Leerink Partnrs Has Pessimistic Outlook of TSBX Q1 Earnings

Turnstone Biologics Corp. (NASDAQ:TSBX) – Investment analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Turnstone Biologics in a research report issued to clients and investors on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch now forecasts that the company will earn ($0.26) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.51) EPS.

Separately, Piper Sandler cut Turnstone Biologics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $3.75 to $0.40 in a report on Wednesday, February 5th.

Turnstone Biologics Trading Down 0.7 %

Shares of NASDAQ TSBX opened at $0.38 on Thursday. The company’s 50-day moving average price is $0.41 and its 200 day moving average price is $0.47. The stock has a market cap of $8.72 million, a price-to-earnings ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 52 week low of $0.34 and a 52 week high of $3.88.

Turnstone Biologics (NASDAQ:TSBX) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.13.

Institutional Trading of Turnstone Biologics

An institutional investor recently raised its position in Turnstone Biologics stock. FMR LLC grew its stake in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) by 3.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,172,987 shares of the company’s stock after buying an additional 37,738 shares during the period. FMR LLC owned 5.07% of Turnstone Biologics worth $653,000 as of its most recent SEC filing. Institutional investors own 52.51% of the company’s stock.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.